Working towards a Group A Streptococcal vaccine: Report of a collaborative Trans-Tasman workshop

Vaccine

Volumn 32, Issue 30, 2014, Pages 3713-3720

  Moreland, Nicole J ^a   Waddington, Claire S ^b   Williamson, Deborah A ^c,d   Sriskandan, Shiranee ^e   Smeesters, Pierre R ^f,g   Proft, Thomas ^c   Steer, Andrew C ^h   Walker, Mark J ⁱ   Baker, Edward N ^a   Baker, Michael G ^j   Lennon, Diana ^c   Dunbar, Rod ^a   Carapetis, Jonathan ^b   Fraser, John D ^c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^g MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ UNIVERSITY OF QUEENSLAND   (Australia)

^j UNIVERSITY OF OTAGO   (New Zealand)

more..

Author keywords

Epidemiology; M protein; Rheumatic fever; Streptococcus pyogenes; Vaccine

Indexed keywords

M PROTEIN; STREPTOCOCCUS VACCINE;

AMINO TERMINAL SEQUENCE; AUSTRALIA AND NEW ZEALAND; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; DEVELOPED COUNTRY; DEVELOPING COUNTRY; GROUP A STREPTOCOCCAL INFECTION; HIGH THROUGHPUT SCREENING; HUMAN; MOLECULAR EPIDEMIOLOGY; PRIORITY JOURNAL; STUDY DESIGN; WORKSHOP; ANIMAL; AUSTRALIA; DISEASE MODEL; HEALTH CARE DISPARITY; NEW ZEALAND; PATHOGENICITY; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES;

ANIMALS; AUSTRALIA; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HEALTHCARE DISPARITIES; HUMANS; MOLECULAR EPIDEMIOLOGY; NEW ZEALAND; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PYOGENES;

EID: 84922249990     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.05.017     Document Type: Conference Paper

References (100)

1. Ralph A.P., Carapetis J.R. Group A streptococcal diseases and their global burden. Curr Top Microbiol Immunol 2012, 368:1-27.
2. Carapetis J.R., Steer A.C., Mulholland E.K., Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005, 5:685-694.
3. Miyake C.Y., Gauvreau K., Tani L.Y., Sundel R.P., Newburger J.W. Characteristics of children discharged from hospitals in the United States in 2000 with the diagnosis of acute rheumatic fever. Pediatrics 2007, 120:503-508.
4. Maguire G.P., Carapetis J.R., Walsh W.F., Brown A.D.H. The future of acute rheumatic fever and rheumatic heart disease in Australia. Med J Aust 2012, 197:133-134.
5. Jaine R., Baker M., Venugopal K. Epidemiology of acute rheumatic fever in New Zealand 1996-2005. J Paediatr Child Health 2008, 44:564-571.
6. Parnaby M.G., Carapetis J.R. Rheumatic fever in indigenous Australian children. J Paediatr Child Health 2010, 46:527-533.
7. Milne R.J., Lennon D.R., Stewart J.M., Vander Hoorn S., Scuffham P.A. Incidence of acute rheumatic fever in New Zealand children and youth. J Paediatr Child Health 2012, 48:685-691.
8. Carapetis J.R., Walker A.M., Hibble M., Sriprakash K.S., Currie B.J. Clinical and epidemiological features of group A streptococcal bacteraemia in a region with hyperendemic superficial streptococcal infection. Epidemiol Infect 1999, 122:59-65.
9. Norton R., Smith H.V., Wood N., Siegbrecht E., Ross A., Ketheesan N. Invasive group A streptococcal disease in North Queensland (1996-2001). Indian J Med Res 2004, 119:148-151.
10. Safar A., Lennon D., Stewart J., Trenholme A., Drinkovic D., Peat B., et al. Invasive group A streptococcal infection and vaccine implications, Auckland, New Zealand. Emerg Infect Dis 2011, 17:983-989.
11. Das D.K., Baker M.G., Venugopal K. Increasing incidence of necrotizing fasciitis in New Zealand: a nationwide study over the period 1990 to 2006. J Infect 2011, 63:429-433.
12. Das D.K., Baker M.G., Venugopal K. Risk factors, microbiological findings and outcomes of necrotizing fasciitis in New Zealand: a retrospective chart review. BMC Infect Dis 2012, 12:348.
13. Steer A.C., Danchin M.H., Carapetis J.R., Group A streptococcal infections in children. J Paediatr Child Health 2007, 43:203-213.
14. Wong W., Lennon D.R., Crone S., Neutze J.M., Reed P.W. Prospective population-based study on the burden of disease from post-streptococcal glomerulonephritis of hospitalised children in New Zealand: epidemiology, clinical features and complications. J Paediatr Child Health 2013, 49:850-855.
15. Hoy W.E., White A.V., Dowling A., Sharma S.K., Bloomfield H., Tipiloura B.T., et al. Post-streptococcal glomerulonephritis is a strong risk factor for chronic kidney disease in later life. Kidney Int 2012, 81:1026-1032.
16. Shaikh N., Swaminathan N., Hooper E.G. Accuracy and precision of the signs and symptoms of streptococcal pharyngitis in children: a systematic review. J Pediatr 2012, 160:487-493. e3.
17. Steer A.C., Jenney A.W.J., Kado J., Batzloff M.R., La Vincente S., Waqatakirewa L., et al. High burden of impetigo and scabies in a tropical country. PLoS Negl Trop Dis 2009, 3:e467.
18. McDonald M.I., Towers R.J., Andrews R.M., Benger N., Currie B.J., Carapetis J.R. Low rates of streptococcal pharyngitis and high rates of pyoderma in Australian aboriginal communities where acute rheumatic fever is hyperendemic. Clin Infect Dis 2006, 43:683-689.
19. Bisno A.L., Rubin F.A., Cleary P.P., Dale J.B. Prospects for a group A streptococcal vaccine: rationale, feasibility, and obstacles-report of a National Institute of Allergy and Infectious Diseases workshop. Clin Infect Dis 2005, 41:1150-1156.
20. Noonan S., Zurynski Y.A., Currie B.J., McDonald M., Wheaton G., Nissen M., et al. A national prospective surveillance study of acute rheumatic fever in Australian children. Pediatr Infect Dis J 2013, 32:e26-e32.
21. Veasy L.G., Tani L.Y., Hill H.R. Persistence of acute rheumatic fever in the intermountain area of the United States. J Pediatr 1994, 124:9-16.
22. Spinetto H., Lennon D., Horsburgh M. Rheumatic fever recurrence prevention: a nurse-led programme of 28-day penicillin in an area of high endemnicity. J Paediatr Child Health 2011, 47:228-234.
23. Gustafsson M.C., Lannergård J., Nilsson O.R., Kristensen B.M., Olsen J.E., Harris C.L., et al. Factor H binds to the hypervariable region of many Streptococcus pyogenes M proteins but does not promote phagocytosis resistance or acute virulence. PLoS Pathog 2013, 9:e1003323.
24. Smeesters P.R., McMillan D.J., Sriprakash K.S. The streptococcal M protein: a highly versatile molecule. Trends Microbiol 2010, 18:275-282.
25. Mora M., Bensi G., Capo S., Falugi F., Zingaretti C., Manetti A.G.O., et al. Group A Streptococcus produce pilus-like structures containing protective antigens and lancefield T antigens. Proc Natl Acad Sci USA 2005, 102:15641-15646.
26. Falugi F., Zingaretti C., Pinto V., Mariani M., Amodeo L., Manetti A.G.O., et al. Sequence variation in group A Streptococcus pili and association of pilus backbone types with lancefield T serotypes. J Infect Dis 2008, 198:1834-1841.
27. Manetti A.G.O., Zingaretti C., Falugi F., Capo S., Bombaci M., Bagnoli F., et al. Streptococcus pyogenes pili promote pharyngeal cell adhesion and biofilm formation. Mol Microbiol 2007, 64:968-983.
28. Proft T., Baker E.N. Pili in Gram-negative and Gram-positive bacteria-structure, assembly and their role in disease. Cell Mol Life Sci 2009, 66:613-635.
29. Kang H.J., Coulibaly F., Clow F., Proft T., Baker E.N. Stabilizing isopeptide bonds revealed in gram-positive bacterial pilus structure. Science 2007, 318:1625-1628.
30. Köller T., Manetti A.G.O., Kreikemeyer B., Lembke C., Margarit I., Grandi G., et al. Typing of the pilus-protein-encoding FCT region and biofilm formation as novel parameters in epidemiological investigations of Streptococcus pyogenes isolates from various infection sites. J Med Microbiol 2010, 59:442-452.
31. Luca-Harari B., Darenberg J., Neal S., Siljander T., Strakova L., Tanna A., et al. Clinical and microbiological characteristics of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol 2009, 47:1155-1165.
32. Lynskey N.N., Lawrenson R.A., Sriskandan S. New understandings in Streptococcus pyogenes. Curr Opin Infect Dis 2011, 24:196-202.
33. Lintges M., van der Linden M., Hilgers R.D., Arlt S., Lahham Al A., Reinert R.R., et al. Superantigen genes are more important than the emm type for the invasiveness of group A Streptococcus infection. J Infect Dis 2010, 202:20-28.
34. Proft T., Fraser J.D. Streptococcal superantigens. Chem Immunol Allergy 2007, 93:1-23.
35. Commons R.J., Smeesters P.R., Proft T., Fraser J.D., Robins-Browne R., Curtis N. Streptococcal superantigens: categorization and clinical associations. Trends Mol Med 2014, 20:48-62.
36. Graham M.R., Smoot L.M., Migliaccio C.A.L., Virtaneva K., Sturdevant D.E., Porcella S.F., et al. Virulence control in group A Streptococcus by a two-component gene regulatory system: global expression profiling and in vivo infection modeling. Proc Natl Acad Sci USA 2002, 99:13855-13860.
37. Walker M.J., Hollands A., Sanderson-Smith M.L., Cole J.N., Kirk J.K., Henningham A., et al. DNase Sda1 provides selection pressure for a switch to invasive group A streptococcal infection. Nat Med 2007, 13:981-985.
38. Sumby P., Whitney A.R., Graviss E.A., DeLeo F.R., Musser J.M. Genome-wide analysis of group A streptococci reveals a mutation that modulates global phenotype and disease specificity. PLoS Pathog 2006, 2:e5.
39. Beall B., Facklam R., Thompson T. Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci. J Clin Microbiol 1996, 34:953-958.
40. Steer A.C., Law I., Matatolu L., Beall B.W., Carapetis J.R. Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. Lancet Infect Dis 2009, 9:611-616.
41. Shulman S.T., Tanz R.R., Dale J.B., Beall B., Kabat W., Kabat K., et al. Seven-year surveillance of North American pediatric group A streptococcal pharyngitis isolates. Clin Infect Dis 2009, 49:78-84.
42. Tartof S.Y., Reis J.N., Andrade A.N., Ramos R.T., Reis M.G., Riley L.W. Factors associated with Group A Streptococcus emm type diversification in a large urban setting in Brazil: a cross-sectional study. BMC Infect Dis 2010, 10:327.
43. McMillan D.J., Drèze P.A., Vu T., Bessen D.E., Guglielmini J., Steer A.C., et al. Updated model of group A Streptococcus M proteins based on a comprehensive worldwide study. Clin Microbiol Infect 2013, 19:E222-E229.
44. Smeesters P.R., McMillan D.J., Sriprakash K.S., Georgousakis M.M. Differences among group A Streptococcus epidemiological landscapes: consequences for M protein-based vaccines?. Expert Rev Vaccines 2009, 8:1705-1720.
45. Carapetis J.R., McDonald M., Wilson N.J. Acute rheumatic fever. Lancet 2005, 366:155-168.
46. Erdem G., Mizumoto C., Esaki D., Reddy V., Kurahara D., Yamaga K., et al. Group A streptococcal isolates temporally associated with acute rheumatic fever in Hawaii: differences from the continental United States. Clin Infect Dis 2007, 45:e20-e24.
47. Pruksakorn S., Sittisombut N., Phornphutkul C., Pruksachatkunakorn C., Good M.F., Brandt E. Epidemiological analysis of non-M-typeable group A Streptococcus isolates from a Thai population in northern Thailand. J Clin Microbiol 2000, 38:1250-1254.
48. Richardson L.J., Towers R.J., Cheng A.C., Currie B.J., Carapetis J.R., Giffard P.M., et al. Diversity of emm sequence types in group A beta-haemolytic streptococci in two remote Northern Territory Indigenous communities: implications for vaccine development. Vaccine 2010.
49. Williamson D., Moreland N.J., Carter P., Upton A., Morgan J., Proft T., et al. Molecular epidemiology of group A streptococcus from pharyngeal isolates in Auckland New Zealand. N Z Med J 2013, 2013.
50. Smeesters P.R., Mardulyn P., Vergison A., Leplae R., Van Melderen L. Genetic diversity of Group A Streptococcus M protein: implications for typing and vaccine development. Vaccine 2008, 26:5835-5842.
51. Smeesters P.R., Vergison A., Campos D., de Aguiar E., Miendje Deyi V.Y., Van Melderen L. Differences between Belgian and Brazilian group A Streptococcus epidemiologic landscape. PLoS ONE 2006, 1:e10.
52. Smeesters P.R., Dramaix M., Van Melderen L. The emm-type diversity does not always reflect the M protein genetic diversity-is there a case for designer vaccine against GAS. Vaccine 2010, 28:883-885.
53. Bloomfield A.L., Felty A.R. Prophylactic vaccination against acute tonsillitis. John Hopkins Hosp Bull 1923, 34:251-253.
54. Steer A.C., Batzloff M.R., Mulholland K., Carapetis J.R. Group A streptococcal vaccines: facts versus fantasy. Curr Opin Infect Dis 2009, 22:544-552.
55. Lancefield R.C. Current knowledge of type-specific M antigens of group A streptococci. J Immunol 1962, 89:307-313.
56. Massell B.F., Honikman L.H., Amezcua J. Rheumatic fever following streptococcal vaccination report of three cases. JAMA 1969, 207:1115-1119.
57. Massell B.F., Michael J.G., Amezcua J., Siner M. Secondary and apparent primary antibody responses after group A streptococcal vaccination of 21 children. Appl Microbiol 1968, 16:509-518.
58. Cunningham M.W. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000, 13:470-511.
59. Guilherme L., Kalil J., Cunningham M. Molecular mimicry in the autoimmune pathogenesis of rheumatic heart disease. Autoimmunity 2006, 39:31-39.
60. Tandon R., Sharma M., Chandrashekhar Y., Kotb M., Yacoub M.H., Narula J. Revisiting the pathogenesis of rheumatic fever and carditis. Nat Rev Cardiol 2013, 10:171-177.
61. McNeil S.A., Halperin S.A., Langley J.M., Smith B., Warren A., Sharratt G.P., et al. Safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 2005, 41:1114-1122.
62. Kotloff K.L., Corretti M., Palmer K., Campbell J.D., Reddish M.A., Hu M.C., et al. Safety and immunogenicity of a recombinant multivalent group A streptococcal vaccine in healthy adults. JAMA 2004, 292:709-715.
63. Dale J.B., Penfound T.A., Chiang E.Y., Walton W.J. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. Vaccine 2011, 29:8175-8178.
64. Batzloff M.R., Hayman W.A., Davies M.R., Zeng M., Pruksakorn S., Brandt E.R., et al. Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8-and diphtheria toxoid-specific antibodies to protection. J Infect Dis 2003, 187:1598-1608.
65. Good M.F. Progress towards developing a vaccine for group A streptococcus based on the M protein. Intern Med J 2002, 32:132-133.
66. Dale J.B., Penfound T., Chiang E.Y., Long V., Shulman S.T., Beall B. Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes. Clin Diagn Lab Immunol 2005, 12:833-836.
67. Hu M.C., Walls M.A., Stroop S.D., Reddish M.A., Beall B., Dale J.B. Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Immun 2002, 70:2171-2177.
68. Dale J.B., Penfound T.A., Tamboura B., Sow S.O., Nataro J.P., Tapia M., et al. Potential coverage of a multivalent M protein-based group A streptococcal vaccine. Vaccine 2013, 31:1576-1581.
69. Engel M.E., Muhamed B., Whitelaw A.C., Musvosvi M., Mayosi B.M., Dale J.B. Group A streptococcal emm type prevalence among symptomatic children in Cape Town and potential vaccine coverage. Pediatr Infect Dis J 2013, 33:208-210.
70. Pandey M., Batzloff M.R., Good M.F. Mechanism of protection induced by group A Streptococcus vaccine candidate J8-DT: contribution of B and T-cells towards protection. PLoS ONE 2009, 4:e5147.
71. Hayman W.A., Brandt E.R., Relf W.A., Cooper J., Saul A., Good M.F. Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A Streptococcus. Int Immunol 1997, 9:1723-1733.
72. Pandey M., Wykes M.N., Hartas J., Good M.F., Batzloff M.R. Long-term antibody memory induced by synthetic peptide vaccination is protective against Streptococcus pyogenes infection and is independent of memory T cell help. J Immunol 2013, 190:2692-2701.
73. Caro-Aguilar I., Ottinger E., Hepler R.W., Nahas D.D., Wu C., Good M.F., et al. Immunogenicity in mice and non-human primates of the group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197. Hum Vaccin Immunother 2012, 9.
74. McArthur J.D., Walker M.J. Domains of group A streptococcal M protein that confer resistance to phagocytosis, opsonization and protection: implications for vaccine development. Mol Microbiol 2006, 59:1-4.
75. Steer A.C., Magor G., Jenney A.W.J., Kado J., Good M.F., McMillan D., et al. emm and C-repeat region molecular typing of beta-hemolytic Streptococci in a tropical country: implications for vaccine development. J Clin Microbiol 2009, 47:2502-2509.
76. Ji Y., Carlson B., Kondagunta A., Cleary P.P. Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A Streptococcus. Infect Immun 1997, 65:2080-2087.
77. Guzmán C.A., Talay S.R., Molinari G., Medina E., Chhatwal G.S. Protective immune response against Streptococcus pyogenes in mice after intranasal vaccination with the fibronectin-binding protein SfbI. J Infect Dis 1999, 179:901-906.
78. Kawabata S., Kunitomo E., Terao Y., Nakagawa I., Kikuchi K., Totsuka K.-I., et al. Systemic and mucosal immunizations with fibronectin-binding protein FBP54 induce protective immune responses against Streptococcus pyogenes challenge in mice. Infect Immun 2001, 69:924-930.
79. Roggiani M., Stoehr J.A., Olmsted S.B., Matsuka Y.V., Pillai S., Ohlendorf D.H., et al. Toxoids of streptococcal pyrogenic exotoxin A are protective in rabbit models of streptococcal toxic shock syndrome. Infect Immun 2000, 68:5011-5017.
80. Sabharwal H., Michon F., Nelson D., Dong W., Fuchs K., Manjarrez R.C., et al. Group A streptococcus (GAS) carbohydrate as an immunogen for protection against GAS infection. J Infect Dis 2006, 193:129-135.
81. Kabanova A., Margarit I., Berti F., Romano M.R., Grandi G., Bensi G., et al. Evaluation of a group A Streptococcus synthetic oligosaccharide as vaccine candidate. Vaccine 2010, 29:104-114.
82. Bensi G., Mora M., Tuscano G., Biagini M., Chiarot E., Bombaci M., et al. Multi high-throughput approach for highly selective identification of vaccine candidates: the group A Streptococcus case. Mol Cell Proteomics 2012, 11. M111.015693-3.
83. Rodríguez-Ortega M.J., Norais N., Bensi G., Liberatori S., Capo S., Mora M., et al. Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat Biotechnol 2006, 24:191-197.
84. Fritzer A., Senn B.M., Minh D.B., Hanner M., Gelbmann D., Noiges B., et al. Novel conserved group A streptococcal proteins identified by the antigenome technology as vaccine candidates for a non-m protein-based vaccine. Infect Immun 2010, 78:4051-4067.
85. Sette A., Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity 2010, 33:530-541.
86. Schneewind O., Missiakas D. Structural vaccinology to thwart antigenic variation in microbial pathogens. Proc Natl Acad Sci USA 2011, 108:10029-10030.
87. Polly S.M., Waldman R.H., High P., Wittner M.K., Dorfman A. Protective studies with a group A streptococcal M protein vaccine. II. Challange of volunteers after local immunization in the upper respiratory tract. J Infect Dis 1975, 131:217-224.
88. Ashbaugh C.D., Moser T.J., Shearer M.H., White G.L., Kennedy R.C., Wessels M.R. Bacterial determinants of persistent throat colonization and the associated immune response in a primate model of human group A streptococcal pharyngeal infection. Cell Microbiol 2000, 2:283-292.
89. Dale J.B., Fischetti V.A., Carapetis J.R., Steer A.C., Sow S., Kumar R., et al. Group A streptococcal vaccines: paving a path for accelerated development. Vaccine 2013, 31(Suppl. 2):B216-B222.
90. Alam F.M., Turner C.E., Smith K., Wiles S., Sriskandan S. Inactivation of the CovR/S virulence regulator impairs infection in an improved murine model of Streptococcus pyogenes naso-pharyngeal infection. PLoS ONE 2013, 8:e61655.
91. Granoff D.M. Review of meningococcal group B vaccines. Clin Infect Dis 2010, 50(Suppl 2):S54-S65.
92. Borrow R., Carlone G.M., Rosenstein N., Blake M., Feavers I., Martin D., et al. Neisseria meningitidis group B correlates of protection and assay standardization-international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 2006, 24:5093-5107.
93. de Malmanche S.A., Martin D.R. Protective immunity to the group A Streptococcus may be only strain specific. Med Microbiol Immunol 1994, 183:299-306.
94. Bauer M.J., Georgousakis M.M., Vu T., Henningham A., Hofmann A., Rettel M., et al. Evaluation of novel Streptococcus pyogenes vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein. Vaccine 2012, 30:2197-2205.
95. Kobayashi S.D., Braughton K.R., Whitney A.R., Voyich J.M., Schwan T.G., Musser J.M., et al. Bacterial pathogens modulate an apoptosis differentiation program in human neutrophils. Proc Natl Acad Sci USA 2003, 100:10948-10953.
96. World Health Organization Proceedings of the tenth global vaccine research forum and parallel satellite symposia 2012, Initiative for Vaccine Research (IVR), Geneva.
97. Tong S.Y.C., Andrews R.M., Kearns T., Gundjirryirr R., McDonald M.I., Currie B.J., et al. Trimethopim-sulfamethoxazole compared with benzathine penicillin for treatment of impetigo in Aboriginal children: a pilot randomised controlled trial. J Paediatr Child Health 2010, 46:131-133.
98. Sciences A.O.M. Microbial challenge studies of human volunteers 2005, Academy of Medical Sciences, London.
99. D'Alessandri R., Plotkin G., Kluge R.M., Wittner M.K., Fox E.N., Dorfman A., et al. Protective studies with group A streptococcal M protein vaccine III. Challenge of volunteers after systemic or intranasal immunization with Type 3 or Type 12 group A Streptococcus. J Infect Dis 1978, 138:712-718.
100. Fox E.N., Waldman R.H., Wittner M.K., Mauceri A.A., Dorfman A. Protective study with a group A streptococcal M protein vaccine Infectivity challenge of human volunteers. J Clin Invest 1973, 52:1885-1892.